Our companies are changing lives.
The integration of precision medicine through biomarker-targeted therapies
The Genovyn family of companies.
A family of innovative cures for the future
At Genovyn, our family of investigational therapies is designed to take on some of the most devastating cancers with limited treatment options. Tripsovyn is being developed to address triple-negative breast cancer, Panovyn targets the challenges of pancreatic cancer, and Immunovyn focuses on immunological disease. Together with our proprietary data mining division — Datavyn — these programs reflect our mission to push beyond traditional pathways, harnessing cutting-edge science and artificial intelligence to bring new hope to patients where it is needed most.
Targeting triple negative breast cancer
We are proud to introduce Tripsovyn, a groundbreaking advancement in the fight against Triple-Negative Breast Cancer (TNBC). Now in preclinical development, Tripsovyn is built on a series of three small molecules and four novel drug combinations that act independently of estrogen receptors, progesterone receptors, and the human epidermal growth factor receptor 2 (HER2). This distinct approach opens new possibilities for addressing one of the most aggressive and treatment-resistant forms of breast cancer.
In parallel, we are developing a companion diagnostic (CDx) that uses a simple test to categorize patients and match them with the most effective therapy based on their unique biology. Together, Tripsovyn and its CDx represent a transformative step toward personalized cancer care—delivering precision, hope, and renewed possibilities to patients who need it most.
Targeting pancreatic cancer for patients
Panovyn represents Genovyn’s bold approach to one of the toughest challenges in oncology: pancreatic cancer. Known for its late detection and limited treatment success, pancreatic cancer demands new thinking. Panovyn is being developed with innovative mechanisms intended to bypass traditional pathways and directly confront the biological barriers that make this disease so aggressive.
Rather than following a one-size-fits-all approach, we are also advancing tools to better identify which patients are most likely to benefit. By combining Panovyn with cutting-edge diagnostics, our aim is to give patients and physicians a clearer path forward—bringing much-needed precision and possibility to an area where hope has too often been in short supply.
Targeting Various Immunological diseases
Imunovyn is pioneering the discovery and development of next-generation therapies that recalibrate the immune system to treat cancer and autoimmune diseases. Our mission is to harness the shared biology of immune dysregulation — restoring immune activation where it is suppressed in cancer, and tempering it where it is overactive in autoimmunity.
We combine AI-driven target discovery, multi-omic patient data, and translational immunology to identify and develop precise, context-dependent therapeutics. Our proprietary discovery engine integrates single-cell and spatial immune profiling with predictive modeling to design first-in-class and best-in-class drugs that correct immune imbalance without compromising safety.
The Knowledge Required to Save Lives
Datavyn is the research and data intelligence arm of Genovyn, dedicated to transforming complex biological insights into actionable breakthroughs. By integrating multi-omics data, clinical outcomes, and real-world evidence, Datavyn empowers discovery and development across Genovyn’s therapeutic portfolio.
Through advanced analytics, AI-driven modeling, and precision data curation, Datavyn accelerates the translation of science into solutions—bringing clarity to complexity and guiding smarter, faster innovation.
We’re on our way to a cure.
We have successfully identified these novel therapies through our proprietary AI platform, which is fully integrated with our world-class preclinical laboratory operations.
The key features of this initiative include:
- Unmet Need: Addressing a significant unmet medical need in the challenging field of TNBC
- Reduced Risk: Seven promising treatment candidates that help reduce investment risk
- AI-Driven Process: Integrated AI-driven support that accelerates development, reduces costs, and improves outcomes(1)
- Precision Medicine: The integration of precision medicine through biomarker-targeted therapies
